Arena Pharma (ARNA) Tops Q4 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Arena Pharma (ARNA) PT Raised to $63 at Credit Suisse
February 27, 2019 8:02 AM ESTCredit Suisse analyst Martin Auster raised the price target on Arena Pharma (NASDAQ: ARNA) to $63.00 (from $61.00) while maintaining a Outperform rating.
... MoreArena Pharma (ARNA) PT Raised to $79 at RBC Capital
February 27, 2019 6:43 AM ESTRBC Capital analyst Kennen MacKay raised the price target on Arena Pharma (NASDAQ: ARNA) to $79.00 (from $70.00) while maintaining a Outperform rating.
Flush with cash, ARNA positions to execute in the clinic in 2019, MacKay comments.
... More


